Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
83 hedge funds and large institutions have $43.4M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 16 closing their positions.
56% more call options, than puts
Call options by funds: $1.21M | Put options by funds: $778K
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
1% less funds holding
Funds holding: 84 → 83 (-1)
67% less capital invested
Capital invested by funds: $130M → $43.4M (-$86.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.16M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$2.04M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.39M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$938K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$848K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.1M |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$4.15M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$968K |
| 5 |
DA
DSC Advisors
Chicago,
Illinois
|
-$942K |
FRTX Hedge Fund Activity: Q3 2013 in Review
83 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2013, worth a combined $43.4M — down 67% from $130M a quarter earlier.
Fund positioning in FRTX was balanced in Q3 2013: 16 funds opened new positions, 16 closed out, 21 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $7.16M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $14.7M sold.
- 83 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2013, down from 84 in Q2 2013.
- Funds reported $43.4M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2013, down 67% quarter-over-quarter.
- 16 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2013 and 16 closed out, a net change of 0 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2013 was Fidelity Investments, an estimated $7.16M added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2013 was T. Rowe Price Associates, an estimated $14.7M sold.
Based on aggregated 13F filings for Q3 2013.